PARPi: Precision Medicine in Advanced Prostate Cancer Webcast (2023)

The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered. The first in the series, PARPi: Precision Medicine in Advanced Prostate Cancer features a multidisciplinary panel, including a urologist, oncologist, and APP, to present the latest advances in PARPi. The expert faculty will engage in an interactive, case-based discussion amongst each other and engage with the learners through Q&A.


This educational activity is supported by an independent educational grant from:

  • Pfizer, Inc.

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners, Physician Assistants, Nurse Navigators)

Learning Objectives

At the conclusion of this activity, the learner will be able to:

  1.  Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class.
  2.  Describe the role of PARPi treatment alone and in combination with other cancer based therapies.
  3.  Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors.
  4.  Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Antonarakis, EmmanuelJanssenConsultant or AdvisorCurrent
Antonarakis, EmmanuelSanofiConsultant or AdvisorCurrent
Antonarakis, EmmanuelMerckConsultant or AdvisorCurrent
Antonarakis, EmmanuelAstraZenecaConsultant or AdvisorCurrent
Antonarakis, EmmanuelQIAGENIntellectual PropertyCurrent
Antonarakis, EmmanuelAmgenConsultant or Advisor12/09/2022
Antonarakis, EmmanuelAstellasScientific Study or Trial04/30/2022
Antonarakis, EmmanuelBayerConsultant or Advisor02/28/2023
Antonarakis, EmmanuelBristol Myers-SquibbScientific Study or TrialCurrent
Antonarakis, EmmanuelNovartisScientific Study or TrialCurrent
Antonarakis, EmmanuelTempusConsultant or Advisor04/01/2022
Antonarakis, EmmanuelBayerScientific Study or TrialCurrent
Antonarakis, EmmanuelAadi BioscienceConsultant or AdvisorCurrent
Antonarakis, EmmanuelAikido PharmaConsultant or Advisor02/04/2022
Antonarakis, EmmanuelBayerScientific Study or TrialCurrent
Antonarakis, EmmanuelBlue Earth DiagnosticsConsultant or Advisor05/31/2023
Antonarakis, EmmanuelConstellation PharmaScientific Study or Trial05/01/2023
Antonarakis, EmmanuelCorcept TherapeuticsConsultant or Advisor03/01/2022
Antonarakis, EmmanuelFoundation MedicineConsultant or AdvisorCurrent
Antonarakis, EmmanuelHookipa PharmaConsultant or Advisor10/14/2022
Antonarakis, EmmanuelMenarini Silicon BiosystemsConsultant or Advisor11/30/2022
Antonarakis, EmmanuelMerckScientific Study or TrialCurrent
Antonarakis, EmmanuelOrionScientific Study or TrialCurrent
Antonarakis, EmmanuelPfizerConsultant or Advisor02/01/2022
Antonarakis, EmmanuelPropella TherapeuticsConsultant or Advisor08/04/2023
Antonarakis, Emmanuelz-AlphaConsultant or Advisor02/03/2023
Pratz, CarolineMerckMeeting Participant or LecturerCurrent
Pratz, CarolineSeagenMeeting Participant or LecturerCurrent
Ross, Ashley E.GenomeDx BiosciencesConsultant or AdvisorCurrent
Ross, Ashley E.JanssenConsultant or AdvisorCurrent
Ross, Ashley E.PfizerConsultant or AdvisorCurrent
Ross, Ashley E.Blue EarthConsultant or AdvisorCurrent
Ross, Ashley E.TEMPUSConsultant or AdvisorCurrent
Ross, Ashley E.BayerConsultant or AdvisorCurrent
Ross, Ashley E.MyovantConsultant or AdvisorCurrent
Ross, Ashley E.AstellasConsultant or AdvisorCurrent
Ross, Ashley E.VeracyteConsultant or AdvisorCurrent
Ross, Ashley E.LantheusConsultant or AdvisorCurrent


PDF icon Education Council Disclosures 2023.pdf


PDF icon COI Review Work Group Disclosures_2023.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.


Method of Participation: Learners will participate in this online educational activity by viewing the webcast and/or listening to the podcast, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.0 hours

Release Date: November, 2023
Expiration Date: November, 2024

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.